What is the current North America Glucagon-like Peptide-1 Agonists Market size?

In 2024, the North America Glucagon-like Peptide-1 Agonists Market size is expected to reach USD 6.94 billion. Read More

Who are the key players in North America Glucagon-like Peptide-1 Agonists Market?

Astrazeneca, Sanofi, Eli Lilly and Company, Pfizer Inc. and Novo Nordisk A/S are the major companies operating in the North America Glucagon-like Peptide-1 Agonists Market. Read More

What years does this North America Glucagon-like Peptide-1 Agonists Market cover, and what was the market size in 2023?

In 2023, the North America Glucagon-like Peptide-1 Agonists Market size was estimated at USD 6.99 billion. The report covers the North America Glucagon-like Peptide-1 Agonists Market historical market size for years: 2018, 2019, 2020, 2021, 2022 and 2023. The report also forecasts the North America Glucagon-like Peptide-1 Agonists Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029. Read More

North America Glucagon-like Peptide-1 Agonists Market Share

Statistics for the 2023 & 2024 North America Glucagon-like Peptide-1 Agonists market share, created by Mordor Intelligence™ Industry Reports. North America Glucagon-like Peptide-1 Agonists share report includes a market forecast to 2029 and historical overview. Get a sample of this industry share analysis as a free report PDF download.

Market Share of North America Glucagon-like Peptide-1 Agonists Industry

The North America Glucagon-like Peptide-1 (GLP-1) Agonists Market is consolidated with major manufacturers, namely Eli Lilly, Sanofi, Novo Nordisk, AstraZeneca, etc.